Frontlight ResearchEarly access
Not yet recruitingPhase 2
Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries
Key facts
- Who runs it
- Astrocyte Pharmaceuticals Inc.
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 48 people, planned
- Started
- 11 May 2026
- Expected to end
- 1 Jun 2028
- Type of study
- Interventional
- Record updated
- 19 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Adult - age 18-70 years
- Complicated-mild TBI - defined as Glasgow Coma Scale (GCS) 13-15 with traumatic lesions on head CT scan obtained in the ED
- Subject has minor or no extracranial injuries
- Injuries do not require admission to an intensive care unit
- Able to initiate treatment with AST-004 within 12h from injury
- Male and female participants of childbearing potential must agree to use an effective method of birth control or abstain from sexual relations that could result in pregnancy for 14 days after receiving treatment with AST-004
- Informed Consent obtained from patient or a legally authorized representative (LAR)
Who cannot take part
- Current abuse of any drugs that are illegal under the Dutch country law
- Administration within the past 90 d of darolutamide, eltrombopag, febuxostat, fostamatinib, teriflunomide or need to administer these medications during the first 48 hours post-dose
- Subject is under the influence of alcohol, any stimulant, nitrates, mind alternating illicit drug or of alternative medications or supplements with stimulant properties (e.g., ephedra) or vasodilatory properties (e.g., nitrate containing supplements) and in the opinion of the Investigator alters ability to complete study assessments and/or study results
- Prior TBI within the previous 6 months
- Patients who require acute surgical and/or neurosurgical interventions or sedation requiring endotracheal intubation
- Known end-stage renal disease or receiving dialysis of any form
- Participant has a pre-injury cognitive impairment that prevents them from completing clinical assessments as required
- Known history of seizures including febrile seizures or a first degree relative with epilepsy
- Subject has a major neurological (e.g., a history of a brain tumor, neurosurgery, stroke or transient ischemic attack (TIA), etc.) or psychiatric/behavioral disorder co-morbidity
- Current enrollment in another interventional, therapeutic clinical study that may affect the results of this study (an observational study is acceptable)
- Administration of, or plans for, a blood transfusion during study participation
- Non-Dutch or English speaking ability or illiteracy that would interfere with understanding follow-up questionnaires
- Time of injury cannot be determined
- Females breastfeeding/lactating or with a positive pregnancy test
- Venipuncture not feasible
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will evaluate the safety and efficacy of AST-004 as a cerebroprotective treatment for patients with complicated mild TBI.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 19 October 2026